Tamma Roberto, Ingravallo Giuseppe, Gaudio Francesco, d'Amati Antonio, Masciopinto Pierluigi, Bellitti Emilio, Lorusso Loredana, Annese Tiziana, Benagiano Vincenzo, Musto Pellegrino, Specchia Giorgina, Ribatti Domenico
Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, 70124 Bari, Italy.
Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Medical School, 70124 Bari, Italy.
Cancers (Basel). 2023 May 17;15(10):2803. doi: 10.3390/cancers15102803.
Although classical Hodgkin lymphoma (CHL) is typically curable, 15-25% of individuals eventually experience a relapse and pass away from their disease. In CHL, the cellular microenvironment is constituted by few percent of H/RS (Hodgkin/Reed-Sternberg) tumor cells surrounded from a heterogeneous infiltration of inflammatory cells. The interplay of H/RS cells with other immune cells in the microenvironment may provide novel strategies for targeted immunotherapies. In this paper we analyzed the microenvironment content in CHL patients with responsive disease (RESP) and patients with relapsed/refractory disease to treatment (REL). Our results indicate the increase of CD68 and CD163 macrophages, the increase of PDL-1 cells and of CD34 microvessels in REL patients respective to RESP patients. In contrast we also found the decrease of CD3 and of CD8 lymphocytes in REL patients respective to RESP patients. Finally, in REL patients our results show the positive correlation between CD68 macrophages and PDL-1 cells as well as a negative correlation between CD163 and CD3.
尽管经典型霍奇金淋巴瘤（CHL）通常是可治愈的，但仍有15%-25%的患者最终会复发并死于该疾病。在CHL中，细胞微环境由少数百分比的霍奇金/里德-斯腾伯格（H/RS）肿瘤细胞组成，周围是炎症细胞的异质性浸润。H/RS细胞与微环境中其他免疫细胞的相互作用可能为靶向免疫治疗提供新策略。在本文中，我们分析了疾病有反应（RESP）的CHL患者和治疗后复发/难治性疾病（REL）的CHL患者的微环境成分。我们的结果表明，与RESP患者相比，REL患者中CD68和CD163巨噬细胞增加，PDL-1细胞和CD34微血管增加。相反，我们还发现与RESP患者相比，REL患者中CD3和CD8淋巴细胞减少。最后，在REL患者中，我们的结果显示CD68巨噬细胞与PDL-1细胞之间呈正相关，CD163与CD3之间呈负相关。
